Key Insights

Highlights

Treatment Research

2 treatments under study, led by Fulzerasib Cetuximab N01

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT07789210Phase 2Recruiting

A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases

NCT07581912Phase 2Recruiting

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

Showing all 2 trials

Research Network

Common Treatments

  • Fulzerasib Cetuximab N011
  • Neoadjuvant Therapy Of Encorafenib Plus Cetuximab N01 And Mfolfox61

Active Sponsors

  • Zhejiang University2

Top Investigators

  • Kefeng Ding1

    Second Affiliated Hospital, Zhejiang University, School of Medicine

  • Kefeng Ding, PhD1

    Second Affiliated Hospital, Zhejiang University, School of Medicine

Related Conditions

  • Colorectal Cancer2
  • Fulzerasib1
  • Kras G12c Mutant Advanced Solid Tumors1
  • Braf V600e Mutation Positive1
  • Encorafenib1

Activity Timeline